Vaxart Anticipates Phase 2b COVID-19 Trial Data in Q2 2026, Reports $61M Cash Runway
Event summary
- Vaxart expects topline data from the 400-person sentinel cohort of its Phase 2b COVID-19 trial in Q2 2026.
- The company reported $61.0 million in cash, cash equivalents, and investments as of March 31, 2026, with a runway into Q2 2027.
- Vaxart entered a share purchase agreement with Lincoln Park Capital Fund, LLC, allowing it to sell up to $25 million of common stock over 24 months.
- The company appointed Dr. James B. Breitmeyer to its Board of Directors, bringing extensive experience in clinical development and regulatory pathways.
The big picture
Vaxart's focus on oral recombinant vaccines positions it uniquely in the biotech sector, aiming to eliminate the need for refrigeration and needle-stick injuries. The company's strategic partnerships, such as with BARDA and Dynavax, and its recent board appointment underscore its commitment to advancing its clinical pipeline. The upcoming data from the Phase 2b COVID-19 trial could significantly impact its market positioning and investor confidence.
What we're watching
- Clinical Trial Outcomes
- The pace at which Vaxart releases and interprets topline data from the Phase 2b COVID-19 trial will determine the next steps for its oral pill vaccine.
- Financial Strategy
- Whether Vaxart can extend its cash runway beyond Q2 2027 through business development partnerships and non-dilutive funding options.
- Regulatory Pathways
- How Dr. James B. Breitmeyer's experience will influence Vaxart's navigation of complex regulatory pathways for its vaccine pipeline.
Related topics